SCHEMBL6806762

SCHEMBL6806762

CCCOc1ccc(S(C)(=O)=O)cc1C(=O)Nc1c(CC)n[nH]c1C(N)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.38
LMNA P02545 3/20 0.37
ADRA2A P08913 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
DRD2 P14416 1/20 0.37
TSHR P16473 1/20 0.37
DRD3 P35462 1/20 0.37
HTR2B P41595 1/20 0.37
STAT6 P42226 1/20 0.37
KCNH2 Q12809 1/20 0.37
BLM P54132 1/20 0.37
SLC6A9 P48067 1/20 0.37
MAPT P10636 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE5A O76074 4/20 0.36
S1PR3 Q99500 1/20 0.36
MRGPRX1 Q96LB2 1/20 0.36
PDE4D Q08499 1/20 0.35
HDAC1 Q13547 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6807424 0.89 SLC6A9 (0.40) RXFP1LMNAADRA2ACYP2D6CYP2C9
SCHEMBL6806862 0.85 POLB (0.40) RXFP1LMNAADRA2ACYP2D6CYP2C9
SCHEMBL6332171 0.83 BRD4 (0.48) RXFP1LMNAADRA2AHTR2BMAPT
SCHEMBL6199158 0.77 BRD4 (0.47) RXFP1LMNAADRA2AHTR2BMAPT
SCHEMBL13659029 0.75 PDE5A (0.37) RXFP1LMNAMAPTHSD17B10PDE5A
SCHEMBL12317587 0.74 PDE5A (0.36) RXFP1PDE5AMAPK1TERT
SCHEMBL6799966 0.74 POLB (0.38) RXFP1LMNADRD3HTR2BBLM
SCHEMBL3133104 0.73 CA2 (0.35) RXFP1LMNAADRA2ACYP2D6CYP2C9
SCHEMBL6801848 0.73 TERT (0.37) LMNAADRA2ACYP2D6DRD2TSHR
SCHEMBL6810517 0.73 PDE5A (0.40) LMNAADRA2ACYP2D6CYP2C9DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6770645-B2 SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS PFIZER INC. 2004-08-03 US disclosed
US-20030064990-A1 Pharmaceutically active compounds PFIZER INC. 2003-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064990-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A RXFP1 47/4885LMNA 2151/4885ADRA2A 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.